Comments: This is not a Urology Update. The U.S. Food and Drug Administration approved Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn), a mixture of three monoclonal antibodies, as the first FDA-approved treatment for Zaire ebolavirus (Ebola virus) infection in adult and pediatric patients. In the PALM trial, the safety and efficacy of Inmazeb was evaluated in a […]
Monthly Archives: October 2020
News Media & Publications
Disitamab Vedotin granted FDA breakthrough therapy designation in bladder cancer
01
Oct
Oct
Comments: The U.S. FDA has granted Disitamab Vedotin (RC48) a breakthrough therapy designation for the treatment of patients with HER2-positive locally advanced or metastatic urothelial carcinoma following treatment with platinum-based chemotherapy. This does not equate to approval of the product, but will expedite the development and review of disitamab vedotin in this setting. Dr Rajeentheran […]